Market Overview:
The global sex cord gonadal stromal tumor treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of sex cord gonadal stromal tumors, increasing awareness about the available treatment options, and technological advancements in the field of cancer treatment. The global sex cord gonadal stromal tumor treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into chemotherapy, radiotherapy, surgery, and others. On the basis of application, the market is segmented into hospitals, clinics,, cancer research centers,, and others. The regional segments are North America,, Latin America,, Europe,,,, Asia Pacific,,,,and Middle East & Africa,.
Product Definition:
Sex cord gonadal stromal tumors (SCGSTs) are a type of tumor that can develop in the ovaries or testes. These tumors are rare, accounting for only about 1% of all ovarian cancers and 3% of all testicular cancers. SCGSTs can be either benign (noncancerous) or cancerous. Treatment for SCGSTs depends on whether the tumor is benign or cancerous and on the location and size of the tumor.
ChemOthersapy:
Chemotherapies are the drugs used to treat cancer. Chemotherapy may be given together with radiation therapy, surgery or a combination of both. The drug or medication which is used for treating cancer has different names depending upon the type of tumor it is intended for; these include cytotoxic agents, antimetabolites and alkylating agents.
RadiOthersapy:
RadiOthersapy is a treatment for Sex Cord Gonadal Stromal Tumor (SCGST) that uses radiation therapy to treat the tumor. The other therapies used in this treatment includes chemotherapy, immunotherapy, and surgery. Chemotherapy alone has limited success rates in treating SCGST; thus it is combined with radiotherapy to increase its effectiveness.
The types of tumors treated by RadiOthersapy include non-seminomas and seminomas.
Application Insights:
Based on application, the global sex cord gonadal stromal tumor treatment market is segmented into hospitals, clinics and cancer research centers. Hospitals held the largest share of over 70% in 2017. This large share can be attributed to factors such as availability of advanced healthcare facilities and highly skilled medical staffs that are capable of handling complex cases. Moreover, hospitals offer a conducive environment for patients suffering from SCT to undergo Chemotherapy or Radiation Therapy thus contributing towards a larger market share for this segment.
The clinics & cancer research centers are anticipated to witness lucrative growth during the forecast period owing to increasing awareness about available treatments along with rising incidences of SCTs across various regions including North America, Europe and Asia Pacific which provides an impetus towards conducting clinical trials leading toward approval from regulatory authorities which eventually aids in boosting product demand at this end-use level thereby propelling growth during the forecast period.
Regional Analysis:
Asia Pacific is expected to be the fastest growing regional market with a CAGR of XX% over the forecast period. The presence of high unmet medical needs, increasing healthcare expenditure, and rising awareness about these tumors are some factors responsible for rapid growth in this region. In addition, availability of skilled doctors and improvement in healthcare infrastructure will drive the market during the forecast period.
In 2016, China sex cord stromal tumor treatment was approved by CFDA (China Food & Drug Administration). This approval opened up new avenues for CCSGTx treatment in China as well as other Asian countries including India and Japan; however, currently there is no commercialized product available in these countries due to regulatory issues involved with its approval process or because it has not been approved yet.
Growth Factors:
- Increasing incidence of sex cord gonadal stromal tumors
- Growing awareness about the early diagnosis and treatment of sex cord gonadal stromal tumors
- Rising demand for better and advanced treatment options for sex cord gonadal stromal tumors
- Technological advancements in the field of diagnostics and treatment of sex cord gonadal stromal tumors
- Availability of government funding for research on sex cord gonadal stromal tumor
Scope Of The Report
Report Attributes
Report Details
Report Title
Sex Cord Gonadal Stromal Tumor Treatment Market Research Report
By Type
ChemOthersapy, RadiOthersapy, Surgery, Others
By Application
Hospitals, Clinics, Cancer Research Centers, Others
By Companies
Abbott, Danaher, Roche, BD, Boston Scientific, Johnson & Johnson, Bio-Rad, Merck Millipore, Agilent Technologies, Thermo Fisher Scientific, Qiagen, PerkinElmer, CooperSurgical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Sex Cord Gonadal Stromal Tumor Treatment Market Report Segments:
The global Sex Cord Gonadal Stromal Tumor Treatment market is segmented on the basis of:
Types
ChemOthersapy, RadiOthersapy, Surgery, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Cancer Research Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Danaher
- Roche
- BD
- Boston Scientific
- Johnson & Johnson
- Bio-Rad
- Merck Millipore
- Agilent Technologies
- Thermo Fisher Scientific
- Qiagen
- PerkinElmer
- CooperSurgical
Highlights of The Sex Cord Gonadal Stromal Tumor Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ChemOthersapy
- RadiOthersapy
- Surgery
- Others
- By Application:
- Hospitals
- Clinics
- Cancer Research Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sex Cord Gonadal Stromal Tumor Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sex cord tumor treatment is a combination of surgery, radiation therapy, and chemotherapy. Surgery removes the tumor while radiation therapy and chemotherapy kill any remaining cancer cells.
Some of the major companies in the sex cord gonadal stromal tumor treatment market are Abbott, Danaher, Roche, BD, Boston Scientific, Johnson & Johnson, Bio-Rad, Merck Millipore, Agilent Technologies, Thermo Fisher Scientific, Qiagen, PerkinElmer, CooperSurgical.
The sex cord gonadal stromal tumor treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sex Cord Gonadal Stromal Tumor Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sex Cord Gonadal Stromal Tumor Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sex Cord Gonadal Stromal Tumor Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sex Cord Gonadal Stromal Tumor Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sex Cord Gonadal Stromal Tumor Treatment Market Size & Forecast, 2020-2028
4.5.1 Sex Cord Gonadal Stromal Tumor Treatment Market Size and Y-o-Y Growth
4.5.2 Sex Cord Gonadal Stromal Tumor Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ChemOthersapy
5.2.2 RadiOthersapy
5.2.3 Surgery
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Cancer Research Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sex Cord Gonadal Stromal Tumor Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sex Cord Gonadal Stromal Tumor Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ChemOthersapy
9.6.2 RadiOthersapy
9.6.3 Surgery
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Cancer Research Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ChemOthersapy
10.6.2 RadiOthersapy
10.6.3 Surgery
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Cancer Research Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ChemOthersapy
11.6.2 RadiOthersapy
11.6.3 Surgery
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Cancer Research Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ChemOthersapy
12.6.2 RadiOthersapy
12.6.3 Surgery
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Cancer Research Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ChemOthersapy
13.6.2 RadiOthersapy
13.6.3 Surgery
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Cancer Research Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sex Cord Gonadal Stromal Tumor Treatment Market: Competitive Dashboard
14.2 Global Sex Cord Gonadal Stromal Tumor Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott
14.3.2 Danaher
14.3.3 Roche
14.3.4 BD
14.3.5 Boston Scientific
14.3.6 Johnson & Johnson
14.3.7 Bio-Rad
14.3.8 Merck Millipore
14.3.9 Agilent Technologies
14.3.10 Thermo Fisher Scientific
14.3.11 Qiagen
14.3.12 PerkinElmer
14.3.13 CooperSurgical
